Company Analysis
Sign in

Amneal Pharmaceuticals, Inc. (AMRX)

Nasdaq: AMRX · Pharmaceutical Preparations · filing with the SEC since 2017
Full chart Alerts Compare
Grade5.3
◀ Past 4.9● Present 6.3▶ Future 4.3
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

69 patents granted to the 7 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Amneal Pharmaceuticals, Inc.’s names, not what it holds today.

Patents granted
69
68 utility, 1 design, 1976 to Dec 31, 2025
Granted in 2025
18
Against 9 in 2024 and 7 in 2023
Applications published
91
16 of them in 2025
Names they are printed under
7
its own name, a subsidiary
By yearGrantedApplications published
'11'12'13'14'15'16'17'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals46
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name7 counted
AMNEAL PHARMACEUTICALS LLC its own name
US, as the owner printed on each patent. 3 more under the same name are not counted (printed in CH)
29 granted
26 published
Impax Laboratories, LLC a subsidiary
US, as the owner printed on each patent
28 granted
19 published
Amneal Complex Products Research LLC a subsidiary
US, as the owner printed on each patent
12 granted
23 published
Amneal Pharmaceuticals, LLC its own name
named as the applicant on its applications, in US. 8 more under the same name are not counted (printed in CH)
0 granted
11 published
Impax Laboratories, LLC a subsidiary
named as the applicant on its applications, in US
0 granted
6 published
AMNEAL EU, LIMITED a subsidiary
IE, as the owner printed on each patent
0 granted
3 published
Gemini Laboratories, LLC a subsidiary
US, as the owner printed on each patent
0 granted
3 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Dec 9, 202512,491,164Muco-adhesive, controlled release formulation of levodopa and/or esters of levodopa and uses thereofPharmaceuticalsImpax Laboratories, LLC
Nov 18, 202512,472,144Pharmaceutical composition comprising eliglustatPharmaceuticalsAMNEAL PHARMACEUTICALS LLC
Nov 4, 202512,458,616Levodopa dosing regimenPharmaceuticalsAMNEAL PHARMACEUTICALS LLC
Oct 28, 202512,453,710Levodopa dosing regimenPharmaceuticalsAMNEAL PHARMACEUTICALS LLC
Oct 21, 202512,447,139Levodopa dosing regimenPharmaceuticalsAMNEAL PHARMACEUTICALS LLC
Sep 2, 202512,403,099Muco-adhesive, controlled release formulation of levodopa and/or esters of levodopa and uses thereofPharmaceuticalsImpax Laboratories, LLC
Aug 12, 202512,383,522Baclofen formulations and methods of minimizing patient exposure to metabolite variationsPharmaceuticalsAMNEAL PHARMACEUTICALS LLC
Jul 29, 202512,370,163Levodopa dosing regimenPharmaceuticalsAMNEAL PHARMACEUTICALS LLC
May 20, 202512,303,605Muco-adhesive, controlled release formulation of levodopa and/or esters of levodopa and uses thereofPharmaceuticalsImpax Laboratories, LLC
May 20, 202512,303,482Levodopa dosing regimenPharmaceuticalsAMNEAL PHARMACEUTICALS LLC
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Nov 13, 20252025/0345266READY-TO-INFUSE OXYTOCIN COMPOSITIONSPharmaceuticalsAMNEAL PHARMACEUTICALS LLC
Oct 30, 20252025/0332144PHARMACEUTICAL COMPOSITION COMPRISING ELIGLUSTATPharmaceuticalsAmneal Pharmaceuticals, LLC
Oct 16, 20252025/0319033MUCO-ADHESIVE, CONTROLLED RELEASE FORMULATION OF LEVODOPA AND/OR ESTERS OF LEVODOPA AND USES THEREOFPharmaceuticalsImpax Laboratories, LLC · patent 12,491,164 granted from it
Oct 9, 20252025/0312270READY-TO-INFUSE PHENYLEPHRINE COMPOSITIONSPharmaceuticalsAMNEAL EU, LIMITED
Aug 28, 20252025/0268919COMPOUNDS FOR THE TREATMENT OF CANCEROrganic fine chemistryAmneal Pharmaceuticals, LLC
May 15, 20252025/0152543LEVODOPA DOSING REGIMENPharmaceuticalsAMNEAL PHARMACEUTICALS LLC · patent 12,370,163 granted from it
May 15, 20252025/0152542LEVODOPA DOSING REGIMENPharmaceuticalsAMNEAL PHARMACEUTICALS LLC · patent 12,458,616 granted from it
May 15, 20252025/0152541LEVODOPA DOSING REGIMENPharmaceuticalsAMNEAL PHARMACEUTICALS LLC · patent 12,303,482 granted from it
May 15, 20252025/0152540LEVODOPA DOSING REGIMENPharmaceuticalsAMNEAL PHARMACEUTICALS LLC · patent 12,453,710 granted from it
May 15, 20252025/0152539LEVODOPA DOSING REGIMENPharmaceuticalsAMNEAL PHARMACEUTICALS LLC · patent 12,447,139 granted from it
What it applied for, 2024 to 2025: Pharmaceuticals 28 · Medical technology 1 · Organic fine chemistry 1.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton AMRX · research, not advice